[Treatment of disseminated malignant melanoma. Results are promising, but toxicity is high].
After the promising results achieved with immunotherapy in disseminated malignant melanoma, a disease reported to show little response to chemotherapy, use of combination chemotherapy regimens with interferon or interleukin and interferon has been shown to provide higher response rates and responses of longer duration. A few phase I-II trials on monoclonal antibodies have also been reported. However, toxicity is substantial with these complex combination regimens.
Brunet
A
A
Centre Chirurgical de l'Ouest, La Garenne-Colombes, France.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008545:Melanoma / Q000628:therapy*; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D016898:Interferon-alpha; D009607:Nitrosourea Compounds; D003606:Dacarbazine; D002945:Cisplatin
Traitement du mélanome malin disséminé. Des résultats encourageants mais une toxicité élevée.